clinical trial · NCT07389980
Prospective Trial of the Efficacy and Safety of a Personalized Regimen of High-dose Aflibercept 8mg on Treatment-naive Polypoidal Choroidal Vasculopathy: the PALLAS Trial
Yeungnam University College of Medicine·phase3·recruiting·n = 50
Polypoidal Choroidal VasculopathyPolypoidal Choroidal Vasculopathy (PCV)aflibercept 8 mg
brief summary
The purpose of this study is to evaluate the efficacy and safety of the aflibercept 8 mg used in a personalized regimen, with flexible loading dose and treatment intervals from 8 to 24 weeks in eyes with treatment-naive PCV.
started
Dec 24, 2026
primary completion
Nov 1, 2028
completion
Dec 1, 2028
last updated
Feb 5, 2026
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol